20:50 , Jun 12, 2019 |  BC Extra  |  Financial News

OrbiMed-backed Prelude raises $60M to take PRMT5 program through clinical POC

With $60 million in new series B funding, Prelude hopes to obtain clinical proof-of-concept data for its lead PRMT5 inhibitor for solid tumors or blood cancers. OrbiMed Advisors and one other undisclosed institutional investor backed...
02:10 , Dec 8, 2017 |  BC Innovations  |  Targets & Mechanisms

Epiphenomena at ASH

While it’s no surprise that cell therapy research is dominant in hematology, the emergence of epigenetics as an equally large focus at this year’s ASH meeting is more notable, reinforcing the resurgence of a field...
20:41 , Oct 10, 2017 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Brain cancer Cell culture and mouse studies suggest PRMT5 inhibitors could help treat glioblastoma multiforme (GBM). In human GBM cell lines, shRNA targeting PRMT5 or the PRMT5 inhibitor EPZ015666 decreased proliferation compared with no...
21:55 , Oct 4, 2017 |  BC Extra  |  Preclinical News

Team ties target to GBM progression, identifies biomarker

In a paper published in Cancer Cell , researchers at Massachusetts Institute of Technology and Harvard Medical School used an in vivo short hairpin RNA screen to identify an epigenetic regulator, protein arginine methyltransferase 5...
19:58 , Sep 21, 2017 |  BC Innovations  |  Tools & Techniques

On your marks

With less fanfare than the first two waves, a quiet rise in activity is driving a revival of interest in epigenetics, despite little progress in solving the fundamental challenges that have dogged the field from...
18:46 , May 12, 2017 |  BC Week In Review  |  Company News

Epizyme gets $10 million from GSK under 2011 partnership

Epizyme Inc. (NASDAQ:EPZM) received a $10 million milestone payment from GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) under a 2011 deal to discover and develop small molecule histone methyltransferase inhibitors for cancer and other diseases. The payment triggered...
02:10 , Feb 14, 2017 |  BioCentury  |  Emerging Company Profile

Divide or conquer

Argonaut Therapeutics Ltd. is attacking cancer by inhibiting an epigenetic regulatory protein that controls a dual role for the E2F1 pathway. By inhibiting the PRMT5 enzyme, the company’s molecules flip the pathway from growth and...
07:00 , Oct 20, 2016 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Chronic myelogenous leukemia (CML) Patient sample, cell culture and mouse studies identified an inhibitor of PRMT5 histone methyltransferase activity that could help treat CML. In patient CD34 + hematopoietic stem cells from peripheral blood...
07:00 , Sep 26, 2016 |  BC Week In Review  |  Clinical News

GSK3326595: Phase I started

GlaxoSmithKline began an open-label, U.S. Phase I trial of oral GSK3326595. A dose-escalation portion will evaluate 12.5-400 mg GSK3326595 once or twice daily in up to 42 patients with relapsed and/or refractory solid tumors. A...
07:00 , Apr 21, 2016 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: Methionine adenosyltransferase 2A (MAT2A); protein arginine methyltransferase 5 (PRMT5); RIO kinase 1 (RIOK1); methylthioadenosine phosphorylase (

Cancer INDICATION: Colorectal cancer Cell culture and mouse studies suggest inhibiting the MAT2A / PRMT5 / RIOK1 axis could help treat MTAP-deficient colon cancer. In a human MTAP-deficient colon cancer cell line, shRNA targeting MAT2A,...